Neurologic Wilson's disease

被引:199
作者
Lorincz, Matthew T. [1 ]
机构
[1] Univ Michigan Hlth Syst, Dept Neurol, Ann Arbor, MI 48109 USA
来源
YEAR IN NEUROLOGY 2 | 2010年 / 1184卷
关键词
ceruloplasmin; copper; dysarthria; dystonia; tremor; Parkinsonism; movement disorders; LONG-TERM TREATMENT; HEPATOLENTICULAR DEGENERATION; ZINC THERAPY; AMMONIUM TETRATHIOMOLYBDATE; CLINICAL PRESENTATION; INITIAL THERAPY; FOLLOW-UP; LIVER-TRANSPLANTATION; PENICILLAMINE-THERAPY; PSYCHIATRIC-SYMPTOMS;
D O I
10.1111/j.1749-6632.2009.05109.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Despite a long history, Wilson's disease, an autosomal recessive disease caused by mutations in the ATP7B gene, remains a commonly misdiagnosed import disease. Mutations in ATP7B result in abnormal copper metabolism and subsequent toxic accumulation of copper. Clinical manifestations of neurologic Wilson's disease include variable combinations of dysarthria, dystonia, tremor, and choreoathetosis. Among neurodegenerative diseases, it is unusual in that misdiagnosis and delay in treatment are clinically relevant because treatments can prevent and cure Wilson's disease, if they are given appropriately. If left untreated, Wilson's disease progresses to hepatic failure or severe neurologic disability and death, while those adequately treated have normal life spans. This review focuses on the neurologic features of Wilson's disease, its diagnosis, and treatment options.
引用
收藏
页码:173 / 187
页数:15
相关论文
共 80 条
  • [1] Akil M, 1995, Adv Neurol, V65, P171
  • [2] Wilson disease in septuagenarian siblings: Raising the bar for diagnosis
    Ala, A
    Borjigin, J
    Rochwarger, A
    Schilsky, N
    [J]. HEPATOLOGY, 2005, 41 (03) : 668 - 670
  • [3] Wilson's disease
    Ala, Aftab
    Walker, Ann P.
    Ashkan, Keyoumars
    Dooley, James S.
    Schilsky, Michael L.
    [J]. LANCET, 2007, 369 (9559) : 397 - 408
  • [4] Zinc acetate treatment in Wilson's disease
    Anderson, LA
    Hakojarvi, SL
    Boudreaux, SK
    [J]. ANNALS OF PHARMACOTHERAPY, 1998, 32 (01) : 78 - 87
  • [5] [Anonymous], 2001, WILSONS DIS CLIN GUI
  • [6] BEARN AG, 1960, ANN HUM GENET, V24, P33
  • [7] TREATMENT OF WILSONS-DISEASE WITH AMMONIUM TETRATHIOMOLYBDATE .1. INITIAL THERAPY IN 17 NEUROLOGICALLY AFFECTED PATIENTS
    BREWER, G
    DICK, RD
    JOHNSON, V
    WANG, YX
    YUZBASIYANGURKAN, V
    KLUIN, K
    FINK, JK
    AISEN, A
    [J]. ARCHIVES OF NEUROLOGY, 1994, 51 (06) : 545 - 554
  • [8] Treatment of Wilson disease with ammonium tetrathiomolybdate - IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease
    Brewer, GJ
    Askari, F
    Lorincz, MT
    Carlson, M
    Schilsky, M
    Kluin, KJ
    Hedera, P
    Moretti, P
    Fink, MK
    Tankanow, R
    Dick, RB
    Sitterly, J
    [J]. ARCHIVES OF NEUROLOGY, 2006, 63 (04) : 521 - 527
  • [9] USE OF ZINC COPPER METABOLIC INTERACTIONS IN THE TREATMENT OF WILSON DISEASE
    BREWER, GJ
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 1990, 9 (05) : 487 - 491
  • [10] Treatment of Wilson disease with ammonium tetrathiomolybdate .2. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy
    Brewer, GJ
    Johnson, V
    Dick, RD
    Kluin, KJ
    Fink, JK
    Brunberg, JA
    [J]. ARCHIVES OF NEUROLOGY, 1996, 53 (10) : 1017 - 1025